Avidity’s Phase I/II Success In Myotonic Dystrophy Obscured By Caveats
Dose-Dependent Response Unclear
The US firm’s lead antibody oligonucleotide conjugate candidate has improved muscle strength and mobility in an early muscular dystrophy trial but some experts are disappointed by dose-specific data and a serious adverse event.
